They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
It is developing the drug candidate to potentially treat immunological diseases
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Survey findings released in advance of World Lupus Day on May 10
Formula attenuates 99% of 365 coronaviruses in computer models
Subscribe To Our Newsletter & Stay Updated
